{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:15:52Z","timestamp":1785402952325,"version":"3.56.0"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T00:00:00Z","timestamp":1411603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess bacillus <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>almette\u2013<jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>u\u00e9rin maintenance treatment schedule for non\u2010muscle invasive bladder cancer at 2 years, using one\u2010third of the full dose and fewer instillations every 3 months or 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a prospective, randomized, multicenter study. All patients had an intermediate\u2010 or high\u2010risk non\u2010muscle invasive bladder cancer. They received three weekly instillations of one\u2010third dose bacillus <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>almette\u2013<jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>u\u00e9rin every 6 months (group <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>) and two weekly instillations every 3 months (group <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>) during 3 years. In the two schedules we assessed efficacy, tolerance, leukocyturia and prostate\u2010specific antigen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant difference was observed between the two groups for recurrence at 6, 12 or 18 months. At 2 years, tumor recurrence was observed in 10.9% and muscle invasion in 2.9% of cases. Bacillus <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>almette\u2013<jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>u\u00e9rin tolerance was comparable \u2013 the adverse events score was 0.8 in group <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content> and 1 in group <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u2009=\u20090.242). No statistical correlation was observed between the adverse events score over 2 years, either for leukocyturia (<jats:italic>P<\/jats:italic>\u2009=\u20090.8891) or prostate\u2010specific antigen level (<jats:italic>P<\/jats:italic>\u2009=\u20090.7155). Leukocyturia level was not significantly associated with tumor recurrence or progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>One\u2010third dose maintenance bacillus <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>almette\u2013<jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>u\u00e9rin is effective with no impact on tumor recurrence or muscle invasion. Furthermore, there seems to be no difference in tumor response or side\u2010effects between patients receiving two or three maintenance instillations every 3 months or 6 months. In clinical practice, the use of leukocyturia or total prostate\u2010specific antigen levels do not appear to be useful in predicting bacillus <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>almette\u2013<jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>u\u00e9rin toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.12609","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T23:54:17Z","timestamp":1411689257000},"page":"53-60","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and tolerance of one\u2010third full dose bacillus <scp>C<\/scp>almette\u2013<scp>G<\/scp>u\u00e9rin maintenance therapy every 3 months or 6 months: Two\u2010year results of <scp>URO\u2010BCG<\/scp>\u20104 multicenter study"],"prefix":"10.1111","volume":"22","author":[{"given":"Christian","family":"Pfister","sequence":"first","affiliation":[{"name":"Urology Department Charles Nicolle University Hospital  Rouen France"},{"name":"Clinical Investigation Center Inserm 6204 Onco\u2010Urology Group  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Kerkeni","sequence":"additional","affiliation":[{"name":"Urology Department Charles Nicolle University Hospital  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Rigaud","sequence":"additional","affiliation":[{"name":"Urology Department Nantes University Hospital  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Le Gal","sequence":"additional","affiliation":[{"name":"Urology Department Caen University Hospital  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Saint","sequence":"additional","affiliation":[{"name":"Urology Department Amiens University Hospital  Amiens France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[{"name":"Urology Department Lyon University Hospital  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Guy","sequence":"additional","affiliation":[{"name":"Urology Department Clermont Ferrand University Hospital  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Wallerand","sequence":"additional","affiliation":[{"name":"Urology Department Bordeaux University Hospital  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Irani","sequence":"additional","affiliation":[{"name":"Urology Department Poitiers University Hospital  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Soulie","sequence":"additional","affiliation":[{"name":"Urology Department Toulouse University Hospital  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Cancer Committee of the French Urological Association","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64043-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1166-7087(10)70043-9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.09.003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2002.02722.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.006"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01117-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67025-5"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(86)90043-7"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01741551"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.062"},{"issue":"1","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000475204","article-title":"Improving the efficacy of BCG immunotherapy by dose reduction","volume":"27","author":"Pagano F","year":"1995","journal-title":"Eur. Urol."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.04.062"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2006.04.008"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.12.039"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23627"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37707-8"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00357-9"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2007.12.007"},{"key":"e_1_2_8_25_1","first-page":"1242","article-title":"Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors","volume":"11","author":"Saint F","year":"2001","journal-title":"Prog. Urol."}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.12609","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.12609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T02:02:41Z","timestamp":1696471361000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.12609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,25]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/iju.12609"],"URL":"https:\/\/doi.org\/10.1111\/iju.12609","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,25]]}}}